S.Amdt. 1917

SA 1917. Mr. RUBIO (for himself and Mr. Coons) submitted an amendment
intended to be proposed to amendment SA 1502 proposed by Mr. Schumer to
the bill S. 1260, to establish a new Directorate for Technology and
Innovation in the National Science Foundation, to establish a regional
technology hub program, to require a strategy and report on economic
security, science, research, innovation, manufacturing, and job
creation, to establish a critical supply chain resiliency program, and
for other purposes; which was ordered to lie on the table; as follows:
At the end of section 2402 of division B, add the
following:

[[Page S3313]]

(k) Reviews and Recommendations Regarding Technology at the
Centers for Innovation in Advanced Development and
Manufacturing and the Medical Countermeasures Advanced
Development and Manufacturing Facility.--
(1) In general.--The Secretary of Commerce, acting through
the Under Secretary of Commerce for Standards and Technology,
shall seek to enter into an agreement with the National
Institute for Innovation in Manufacturing Biopharmaceuticals
(NIIMBL) to perform the services covered by this subsection.
(2) Review and recommendations.--Under an agreement between
the Secretary and the National Institute for Innovation in
Manufacturing Biopharmaceuticals, the National Institute for
Innovation in Manufacturing Biopharmaceuticals shall, in
collaboration with the Director of the Biomedical Advanced
Research and Development Authority (BARDA) of the Department
of Health and Human Services and the Secretary of Defense--
(A) review technology at the Centers for Innovation in
Advanced Development and Manufacturing of the Department of
Health and Human Services and the Medical Countermeasures
Advanced Development and Manufacturing facility of the
Department of Defense;
(B) develop recommendations for means to implement
innovative approaches to advance United States domestic
biopharmaceutical manufacturing capabilities and to ensure
that the Centers for Innovation in Advanced Development and
Manufacturing and the Medical Countermeasures Advanced
Development and Manufacturing facility have state-of-the-art
capabilities aligned with those available to the private
sector; and
(C) identify other opportunities and priorities to improve
the United States public health and medical preparedness and
response capabilities and domestic biopharmaceutical
manufacturing capabilities.
______